Entrectinib (Synonyms: 恩曲替尼; NMS-E628; RXDX-101)

目录号: HY-12678 纯度: 99.79%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Entrectinib (NMS-E628) 是口服有效的，可透过血脑屏障的，且具有中枢神经活性的 TrkA/B/C, ROS1 和 ALK 抑制剂，其 IC₅₀ 值分别为 1, 3, 5, 12 和 7 nM。Entrectinib 诱导癌细胞凋亡和周期停滞，具有抗肿瘤活性，还可减轻博来霉素诱导的小鼠肺纤维化。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Entrectinib Chemical Structure

CAS No. : 1108743-60-7

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥1073	In-stock
5 mg	￥870	In-stock
10 mg	￥1200	In-stock
50 mg	￥3000	In-stock
100 mg	￥4500	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Entrectinib:

MCE 顾客使用本产品发表的 21 篇科研文献

: Entrectinib purchased from MCE. Usage Cited in: Cell Rep. 2020 Aug 4;32(5):107994. [Abstract]; Immunoblot analysis of protein expression or modification in lysates of IMPETPR-NTRK1 cells treated with 10 nM Entrectinib for 0-24 h. pTRKA remained completely inhibited at 18 and 24 h, indicating that Entrectinib is still effectively inhibiting its direct target.

: Entrectinib purchased from MCE. Usage Cited in: Mol Cancer Ther. 2017 Oct;16(10):2130-2143. [Abstract]; KM12 or CR20 cells are treated with increasing concentrations of Cabozantinib, Entrectinib or LOXO-101 for 3 hours. Cell lysates are immunoblotted to detect the indicated proteins.

Entrectinib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Trk Receptor 亚型特异性产品:

查看所有亚型

TrkA TrkB TrkC Trk

生物活性
纯度 & 产品资料
参考文献

生物活性

Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC₅₀ values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice^[1]^[2]^[3].

IC₅₀ & Target

IC50: 1 nM (TrkA), 3 nM (TrkB), 5 nM (TrkC), 12 nM (ROS1), 7 nM (ALK)^[2].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	7.46 μM Compound: Entrectinib	Antiproliferative activity against EGFR-positive human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against EGFR-positive human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34534734]
BaF3	IC₅₀	0.003 μM Compound: 2; entrectinib	Inhibition of human TEL (336 residues) fused-TRKA (440 to 796 residues) (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Inhibition of human TEL (336 residues) fused-TRKA (440 to 796 residues) (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 27003761]
BaF3	IC₅₀	0.003 μM Compound: 2; entrectinib	Inhibition of human TEL (336 residues) fused-TRKB (455 to 822 residues) (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Inhibition of human TEL (336 residues) fused-TRKB (455 to 822 residues) (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 27003761]
BaF3	IC₅₀	0.003 μM Compound: 2; entrectinib	Inhibition of human TEL (336 residues) fused-TRKC (454 to 825 residues) (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Inhibition of human TEL (336 residues) fused-TRKC (454 to 825 residues) (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 27003761]
BaF3	IC₅₀	0.005 μM Compound: 2; entrectinib	Inhibition of human TEL (336 residues) fused-ROS1 (1891 to 2347 residues) (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Inhibition of human TEL (336 residues) fused-ROS1 (1891 to 2347 residues) (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 27003761]
BaF3	IC₅₀	0.028 μM Compound: 2; entrectinib	Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 27003761]
BaF3	IC₅₀	0.067 μM Compound: 2; entrectinib	Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 27003761]
BaF3	IC₅₀	0.897 μM Compound: 2; entrectinib	Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay	[PMID: 27003761]
BaF3	IC₅₀	2.104 μM Compound: 2; entrectinib	Cytotoxicity against mouse IL-3 dependent BA/F3 cells incubated for 72 hrs by cell titer-glo assay Cytotoxicity against mouse IL-3 dependent BA/F3 cells incubated for 72 hrs by cell titer-glo assay	[PMID: 27003761]
KARPAS-299	IC₅₀	0.031 μM Compound: 2; entrectinib	Antiproliferative activity against human KARPAS299 cells incubated for 72 hrs by cell titer-glo assay Antiproliferative activity against human KARPAS299 cells incubated for 72 hrs by cell titer-glo assay	[PMID: 27003761]
KARPAS-299	IC₅₀	0.076 μM Compound: Entrectinib	Antiproliferative activity against NPM-ALK addicted human KARPAS-299 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against NPM-ALK addicted human KARPAS-299 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34534734]
KARPAS-299	IC₅₀	31 nM Compound: 84	Antiproliferative activity against human KARPAS299 cells incubated for 48 hrs by sulforhodamine B assay Antiproliferative activity against human KARPAS299 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 31077998]
KM12	IC₅₀	0.0017 μM Compound: 4-3; RXDX-101	Antiproliferative activity against human KM12 cells after 72 hrs Antiproliferative activity against human KM12 cells after 72 hrs	[PMID: 30188734]
KM12	IC₅₀	0.012 μM Compound: Entrectinib	Cytotoxicity against human KM12 cells assessed as reduction in cell viability incubated for 72 hrs by resazurin based assay Cytotoxicity against human KM12 cells assessed as reduction in cell viability incubated for 72 hrs by resazurin based assay	[PMID: 33652352]
KM12	IC₅₀	0.017 μM Compound: 2; entrectinib	Antiproliferative activity against human KM12 cells expressing TRKA protein incubated for 72 hrs by cell titer-glo assay Antiproliferative activity against human KM12 cells expressing TRKA protein incubated for 72 hrs by cell titer-glo assay	[PMID: 27003761]
KM12	IC₅₀	0.057 μM Compound: Entrectinib	Antiproliferative activity against TPM3-NTRK1-addicted human KM12 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against TPM3-NTRK1-addicted human KM12 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34534734]
KM12	IC₅₀	17 nM Compound: 84	Antiproliferative activity against human KM12 cells incubated for 48 hrs by sulforhodamine B assay Antiproliferative activity against human KM12 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 31077998]
KM12	IC₅₀	4.3 nM Compound: Entrectinib	Antiproliferative activity against human KM12 cells expressing TPM3-TRKA assessed as reduction in cell viability measured after 3 days by Celltiter-Glo assay Antiproliferative activity against human KM12 cells expressing TPM3-TRKA assessed as reduction in cell viability measured after 3 days by Celltiter-Glo assay	[PMID: 32550985]
MV4-11	IC₅₀	0.081 μM Compound: 2; entrectinib	Antiproliferative activity against human MV411 cells incubated for 72 hrs by cell titer-glo assay Antiproliferative activity against human MV411 cells incubated for 72 hrs by cell titer-glo assay	[PMID: 27003761]
MV4-11	IC₅₀	81 nM Compound: 84	Antiproliferative activity against human MV4-11 cells incubated for 48 hrs by sulforhodamine B assay Antiproliferative activity against human MV4-11 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 31077998]
NCI-H2228	IC₅₀	0.068 μM Compound: 2; entrectinib	Antiproliferative activity against human NCI-H2228 cells expressing ALK protein incubated for 72 hrs by cell titer-glo assay Antiproliferative activity against human NCI-H2228 cells expressing ALK protein incubated for 72 hrs by cell titer-glo assay	[PMID: 27003761]
NCI-H2228	IC₅₀	0.254 μM Compound: Entrectinib	Antiproliferative activity against EML4-ALK addicted human H2228 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against EML4-ALK addicted human H2228 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34534734]
NCI-H2228	IC₅₀	68 nM Compound: 84	Antiproliferative activity against human NCI-H2228 cells incubated for 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H2228 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 31077998]
SH-SY5Y	IC₅₀	1.6 μM Compound: Entrectinib	Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
SK-N-AS	IC₅₀	4.47 μM Compound: Entrectinib	Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
SU-DHL-1	IC₅₀	0.024 μM Compound: 2; entrectinib	Antiproliferative activity against human SU-DHL1 cells expressing ALK protein incubated for 72 hrs by cell titer-glo assay Antiproliferative activity against human SU-DHL1 cells expressing ALK protein incubated for 72 hrs by cell titer-glo assay	[PMID: 27003761]
SU-DHL-1	IC₅₀	20 nM Compound: 84	Antiproliferative activity against human SU-DHL1 cells incubated for 48 hrs by sulforhodamine B assay Antiproliferative activity against human SU-DHL1 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 31077998]

体外研究
(In Vitro)

Entrectinib (100, 200, 400 nM; 24 h) 缓解 TGF-β1 诱导的小鼠肺成纤维细胞的激活^[1]。
Entrectinib(100, 200, 400 nM; 24 h) 抑制 TGF-β1 诱导的小鼠肺上皮细胞上皮间质转化^[1]。
Entrectinib (10, 50, 250 nM; 2 h) 消除 KM12 细胞中 TPM3-TRKA 的自身磷酸化，同时完全抑制 PLCg1、AKT 和 MAPK 的磷酸化^[2]。
Entrectinib (10, 50, 250 nM; 24, 48 h) 诱导 KM12 细胞周期停滞 (24 小时) 和凋亡 (48 小时)^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	Mouse lung fibroblasts cells
Concentration:	100, 200, 400 nM
Incubation Time:	24 h
Result:	Reduced the protein expression levels of α-SMA, collagen I and fibronectin in the TGF-β1-treated fibroblasts.

Western Blot Analysis^[1]

Cell Line:	Mouse lung epithelial cells
Concentration:	100, 200, 400 nM
Incubation Time:	24 h
Result:	Significantly increased the expression of the epithelial marker Ecadherin and decreased the expression of the mesenchymal markers N-cadherin and Vimentin.

Apoptosis Analysis^[2]

Cell Line:	KM12 cells
Concentration:	10, 50, 250 nM
Incubation Time:	24, 48 h
Result:	Induced accumulation of cells in the G1 phase of the cell cycle at 24 hours treatment, followed by apoptosis induction at 48 hours.

体内研究
(In Vivo)

Entrectinib (20, 40, 60 mg/kg; i.g.; single daily for 7 days) 减轻 Bleomycin 诱导的小鼠肺纤维化^[1]。
Entrectinib (30, 60 mg/kg; p.o.; twice daily for 10 consecutive days) 可诱导荷瘤小鼠中异种移植肿瘤的消退，包括 TRKA 依赖性结直肠癌 KM12、ROS1 驱动的肿瘤和几种不同组织来源的 ALK 依赖性模型，包括脑局部肺模型癌转移^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice (6-8 weeks old, 20-25 g; Bleomycin-induced pulmonary fibrosis model)^[1].
Dosage:	20, 40, 60 mg/kg
Administration:	Intragastric Administration; single daily for 7 days.
Result:	Significantly improved lung function in the pulmonary fibrosis model mice.

Clinical Trial

分子量

560.64

Formula

C₃₁H₃₄F₂N₆O₂

CAS 号

1108743-60-7

性状

固体

颜色

Off-white to light yellow

中文名称

恩曲替尼

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 31 mg/mL (55.29 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7837 mL	8.9184 mL	17.8368 mL
5 mM	0.3567 mL	1.7837 mL	3.5674 mL
10 mM	0.1784 mL	0.8918 mL	1.7837 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (4.46 mM); 澄清溶液
方案二

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.46 mM); 澄清溶液
方案三

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.71 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案四

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (3.71 mM); 悬浊液; 超声助溶

此方案可获得 2.08 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案五

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (3.71 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 0.5% Methyl cellulose/0.5% Tween-80 in Saline water
Solubility: 5 mg/mL (8.92 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.79%

选择批次：

Data Sheet (650 KB) SDS (393 KB)

COA (290 KB) HNMR (281 KB) LCMS (94 KB) 元素分析报告 (213 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Miao Y, et al. Entrectinib ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β1 signaling pathway. Int Immunopharmacol. 2022 Dec;113(Pt B):109427. [Content Brief]

[2]. Ardini E, et al. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Mol Cancer Ther. 2016 Apr;15(4):628-39. [Content Brief]

[3]. Iyer R, et al. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Lett. 2016 Mar 28;372(2):179-86. [Content Brief]

Entrectinib 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.7837 mL	8.9184 mL	17.8368 mL	44.5919 mL
	5 mM	0.3567 mL	1.7837 mL	3.5674 mL	8.9184 mL
	10 mM	0.1784 mL	0.8918 mL	1.7837 mL	4.4592 mL
	15 mM	0.1189 mL	0.5946 mL	1.1891 mL	2.9728 mL
	20 mM	0.0892 mL	0.4459 mL	0.8918 mL	2.2296 mL
	25 mM	0.0713 mL	0.3567 mL	0.7135 mL	1.7837 mL
	30 mM	0.0595 mL	0.2973 mL	0.5946 mL	1.4864 mL
	40 mM	0.0446 mL	0.2230 mL	0.4459 mL	1.1148 mL
	50 mM	0.0357 mL	0.1784 mL	0.3567 mL	0.8918 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Entrectinib (Synonyms: 恩曲替尼; NMS-E628; RXDX-101)

Customer Review

Other Forms of Entrectinib:

MCE 顾客使用本产品发表的 21 篇科研文献

Entrectinib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Trk Receptor 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Entrectinib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Entrectinib (Synonyms: 恩曲替尼; NMS-E628; RXDX-101)

Customer Review

Other Forms of Entrectinib:

Entrectinib 相关抗体

MCE 顾客使用本产品发表的 21 篇科研文献

Entrectinib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Trk Receptor 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Entrectinib 相关抗体:

摩尔计算器

稀释计算器

Entrectinib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z